HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma
Clinical trial NCT02569320 · COMPLETED
Trial details
- NCT number
- NCT02569320
- Sponsor
- Ohio State University Comprehensive Cancer Center
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-05-20
- Primary completion
- 2020-11-14
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.